A study reported the combined use of tocilizumab (anti-IL-6R) and bevacizumab (anti-VEGF) in two patients with recurrent cystic ACPs, resulting in significant responses, including reduced cystic tumor burden and tumor stability, suggesting a viable therapeutic alternative (60). The gene discussed is IL6R; the disease is neoplasm.